XML 60 R41.htm IDEA: XBRL DOCUMENT v3.25.1
Note 2 - Revenue - Disaggregation of Revenue (Details) - USD ($)
$ in Thousands
 12 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Mar. 31, 2023
Revenues [1] $ 240,978 $ 216,187 $ 219,080
Consumables [Member] | Transferred at Point in Time [Member]      
Revenues 138,734 120,976 117,841
Hardware and Software [Member] | Transferred at Point in Time [Member]      
Revenues 59,661 55,820 62,679
Service [Member]      
Revenues 42,583 39,391 38,560
Service [Member] | Transferred at Point in Time [Member]      
Revenues 42,583 39,391 38,560
Operating Segments [Member] | Sterilization and Disinfection Control [Member]      
Revenues [1],[2] 93,418 [3] 75,124 [4] 64,609
Operating Segments [Member] | Clinical Genomics [Member]      
Revenues [1] 47,081 52,588 62,299 [5]
Operating Segments [Member] | Biopharmaceutical Development [Member]      
Revenues [1] 48,730 40,712 47,365
Operating Segments [Member] | Calibration Solutions [Member]      
Revenues [1] 51,749 47,763 44,807
Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Sterilization and Disinfection Control [Member]      
Revenues 82,736 [3] 65,459 [4] 55,605
Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Clinical Genomics [Member]      
Revenues 35,672 36,086 43,374 [5]
Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Biopharmaceutical Development [Member]      
Revenues 17,287 17,086 15,800
Operating Segments [Member] | Consumables [Member] | Transferred at Point in Time [Member] | Calibration Solutions [Member]      
Revenues 3,039 2,345 3,062
Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Sterilization and Disinfection Control [Member]      
Revenues 496 [3] 549 [4] 692
Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Clinical Genomics [Member]      
Revenues 7,689 12,254 13,347 [5]
Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Biopharmaceutical Development [Member]      
Revenues 19,649 12,993 22,079
Operating Segments [Member] | Hardware and Software [Member] | Transferred at Point in Time [Member] | Calibration Solutions [Member]      
Revenues 31,827 30,024 26,561
Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Sterilization and Disinfection Control [Member]      
Revenues 10,186 [3] 9,116 [4] 8,312
Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Clinical Genomics [Member]      
Revenues 3,720 4,248 5,578 [5]
Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Biopharmaceutical Development [Member]      
Revenues 11,794 10,633 9,486
Operating Segments [Member] | Service [Member] | Transferred at Point in Time [Member] | Calibration Solutions [Member]      
Revenues $ 16,883 $ 15,394 $ 15,184
[1] Intersegment revenues are not significant and are eliminated to arrive at consolidated totals. Revenues as presented are consistent with GAAP measurement principles and our CODM's review of segment information.
[2] Includes GKE results beginning upon acquisition in fiscal year 2024.
[3] Revenues of $24,815 from GKE are included in the Sterilization and Disinfection Control division during the year ended March 31, 2025.
[4] Revenues of $9,289 from GKE are included in the Sterilization and Disinfection Control division during the year ended March 31, 2024 and represent sales made beginning from the acquisition date.
[5] Revenues in the Clinical Genomics division represent transactions subsequent to the acquisition of Agena Bioscience, Inc. on October 20, 2021.